Can Radiomics Predict Survival in Patients With NSCLC Receiving Immunotherapy? – The ASCO Post

Immunotherapy with immune checkpoint inhibitors has made great strides in the treatment of many cancers, but only between 25% and 50% of patients respond with clinical benefit, and these agents come with adverse events and high price tags. Thus, preselection of patients who are likely to respond to this type of therapy…

Read the full article here

Related Articles